Freezing UK Statutory Scheme Rebate Could Cost UK Government Over £15m
Accepting the pharmaceutical industry’s request to keep the statutory scheme rebate rate at its current rate this year could cost the government dearly, but raising it as planned could be detrimental for UK life sciences.
You may also be interested in...
The pharmaceutical industry and the UK government are beginning a series of discussions on the shape of the future voluntary drug pricing and access scheme (VPAS), ahead of the formal negotiations that are scheduled to start in April.
In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.